Prana Biotechnology Limited (NASDAQ:PRAN) shares traded down 5.3% during mid-day trading on Tuesday . The company traded as low as $1.41 and last traded at $1.42. 560,972 shares were traded during trading, a decline of 13% from the average session volume of 644,214 shares. The stock had previously closed at $1.50.
Separately, ValuEngine downgraded Prana Biotechnology from a “buy” rating to a “hold” rating in a report on Wednesday, January 2nd.
The firm has a market cap of $12.64 million, a price-to-earnings ratio of -2.29 and a beta of 0.22.
About Prana Biotechnology (NASDAQ:PRAN)
Prana Biotechnology Limited researches and develops therapeutic drugs for the treatment of Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidates include PBT434 that is in Phase I clinical trial for the treatment for Parkinson's disease and other movement disorders; and PBT2, which has completed four Phase I studies and a Phase IIa clinical trial for patients with Alzheimer's disease.
Recommended Story: Why do companies engage in swaps?
Receive News & Ratings for Prana Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prana Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.